Terray Therapeutics — Funding & Company Data

Terray Therapeutics' funding trajectory demonstrates a clear and confident progression from seed to a substantial Series B. The initial, unannounced $20 million seed round allowed the company to operate in stealth before a significant $60 million Series A in 2022 to officially launch and scale its platform. The most recent financing, a $120 million Series B in late 2024, more than doubles its previous round and brings its total funding to a formidable $200 million.

The quality of investors is high, featuring a mix of deep-tech and biotech-focused VCs. The participation of NVentures, NVIDIA's venture arm, in the Series B is a particularly strong endorsement of Terray's computational and AI-heavy approach to drug discovery. This level of financial backing provides a multi-year runway, allowing the company to advance its internal immunology programs into the clinic and continue building its tNova generative AI platform.

From a competitive standpoint, this capital places Terray among the better-funded private biotechs in the AI drug discovery space. It allows them to aggressively scale their proprietary dataset, which they claim is already 50 times larger than all publicly available chemistry data. This data advantage is their core moat. For a potential user or partner, the company's financial stability appears robust, de-risking the platform commitment and suggesting longevity.